SRT-1720 free base | CAS#925434-55-5 | SIRT1 Activator

MedKoo Cat#: 402110 | Name: SRT-1720 free base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SRT-1720, also known as CAY10559 and is a drug developed by Sirtris Pharmaceuticals intended as a small-molecule activator of the sirtuin subtype SIRT1. It has similar activity in the body to the known SIRT1 activator resveratrol, but is 1000x more potent. In animal studies it was found to improve insulin sensitivity and lower plasma glucose levels in fat, muscle and liver tissue, and increased mitochondrial and metabolic function. A study of SRT1720 conducted by the National Institute on Aging found that the drug may extend the lifespan of obese mice by 44% .

Chemical Structure

SRT-1720 free base

CAS#925434-55-5 (free base)

Theoretical Analysis

MedKoo Cat#: 402110

Name: SRT-1720 free base

CAS#: 925434-55-5 (free base)

Chemical Formula: C25H23N7OS

Exact Mass: 469.1685

Molecular Weight: 469.56

Elemental Analysis: C, 63.95; H, 4.94; N, 20.88; O, 3.41; S, 6.83

Price and Availability

Size	Price	Availability
10mg	USD 150.00	Ready to ship
25mg	USD 250.00	Ready to ship
50mg	USD 450.00	Ready to ship
100mg	USD 750.00	Ready to ship
200mg	USD 1,250.00	Ready to ship
500mg	USD 2,650.00	Ready to ship
1g	USD 3,850.00	Ready to ship
2g	USD 5,950.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

925434-55-5 (free base) 1001645-58-4 (HCl)

Synonym

SRT1720; SRT-1720; SRT 1720; CAY10559; CAY-10559; CAY 10559; SIRT-1933; SIRT 1933; SIRT1933.

IUPAC/Chemical Name

N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide

InChi Key

IASPBORHOMBZMY-UHFFFAOYSA-N

InChi Code

InChI=1S/C25H23N7OS/c33-24(22-13-27-20-7-3-4-8-21(20)28-22)29-19-6-2-1-5-18(19)23-15-32-17(16-34-25(32)30-23)14-31-11-9-26-10-12-31/h1-8,13,15-16,26H,9-12,14H2,(H,29,33)

SMILES Code

O=C(C1=NC2=CC=CC=C2N=C1)NC3=CC=CC=C3C4=CN5C(SC=C5CN6CCNCC6)=N4

Appearance

white solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#A9T02K22

QC Data

View QC data: current batch, Lot#A9T02K22

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

SRT 1720 is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM and shows less potent activities agaiinst SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively.

In vitro activity:

SRT1720 alters the brain's energy usage patterns. When SRT1720 was added to guinea pig brain cortical tissue slices, SRT1720 significantly increased 13C incorporation into Krebs cycle metabolites, as well as GABA and glutamine, while decreasing glycolysis-associated metabolites. SRT1720 increased label incorporation from [1,2-13C]acetate, indicating enhanced acetate metabolism with active SIRT1. SRT1720 increased glutamine levels and decreased lactate levels without affecting other measured metabolite pools. J Neurochem. 2017 Mar;140(6):903-918. https://pubmed.ncbi.nlm.nih.gov/27925207/

In vivo activity:

This study highlights SIRT1 as a potential target for treating kidney injuries caused by ischemia-reperfusion. Treating mice SRT1720 reduced kidney damage and improved kidney health. SRT1720 increased cell growth in adult mice after injury. SRT1720 also decreased the expression of p53 in the kidneys. These findings suggest SIRT1 with SRT-1720 can help reduce damage and promote kidney regeneration. Kidney Int. 2013 Mar;83(3):404-13. https://pubmed.ncbi.nlm.nih.gov/23302720/

	Solvent	mg/mL	mM
Solubility
	DMSO	5.0	10.65

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 469.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Rowlands BD, Klugmann M, Rae CD. Acetate metabolism does not reflect astrocytic activity, contributes directly to GABA synthesis, and is increased by silent information regulator 1 activation. J Neurochem. 2017 Mar;140(6):903-918. doi: 10.1111/jnc.13916. Epub 2017 Jan 23. PMID: 27925207. 2. Liang D, Zhuo Y, Guo Z, He L, Wang X, He Y, Li L, Dai H. SIRT1/PGC-1 pathway activation triggers autophagy/mitophagy and attenuates oxidative damage in intestinal epithelial cells. Biochimie. 2020 Mar;170:10-20. doi: 10.1016/j.biochi.2019.12.001. Epub 2019 Dec 9. PMID: 31830513. 3. Jiang T, Liu E, Li Z, Yan C, Zhang X, Guan J, Zhan Y, Zhao B, Ding W. SIRT1-Rab7 axis attenuates NLRP3 and STING activation through late endosomal-dependent mitophagy during sepsis-induced acute lung injury. Int J Surg. 2024 Mar 4. doi: 10.1097/JS9.0000000000001215. Epub ahead of print. PMID: 38445453. 4. Fan H, Yang HC, You L, Wang YY, He WJ, Hao CM. The histone deacetylase, SIRT1, contributes to the resistance of young mice to ischemia/reperfusion-induced acute kidney injury. Kidney Int. 2013 Mar;83(3):404-13. doi: 10.1038/ki.2012.394. Epub 2013 Jan 9. PMID: 23302720.

In vitro protocol:

In vivo protocol:

1. Jiang T, Liu E, Li Z, Yan C, Zhang X, Guan J, Zhan Y, Zhao B, Ding W. SIRT1-Rab7 axis attenuates NLRP3 and STING activation through late endosomal-dependent mitophagy during sepsis-induced acute lung injury. Int J Surg. 2024 Mar 4. doi: 10.1097/JS9.0000000000001215. Epub ahead of print. PMID: 38445453. 2. Fan H, Yang HC, You L, Wang YY, He WJ, Hao CM. The histone deacetylase, SIRT1, contributes to the resistance of young mice to ischemia/reperfusion-induced acute kidney injury. Kidney Int. 2013 Mar;83(3):404-13. doi: 10.1038/ki.2012.394. Epub 2013 Jan 9. PMID: 23302720.

1: Gueguen C, Palmier B, Plotkine M, Marchand-Leroux C, Bessson VC. Neurological and Histological Consequences Induced by In Vivo Cerebral Oxidative Stress: Evidence for Beneficial Effects of SRT1720, a Sirtuin 1 Activator, and Sirtuin 1-Mediated Neuroprotective Effects of Poly(ADP-ribose) Polymerase Inhibition. PLoS One. 2014 Feb 21;9(2):e87367. doi: 10.1371/journal.pone.0087367. eCollection 2014. PubMed PMID: 24586272; PubMed Central PMCID: PMC3931616. 2: Mitchell SJ, Martin-Montalvo A, Mercken EM, Palacios HH, Ward TM, Abulwerdi G, Minor RK, Vlasuk GP, Ellis JL, Sinclair DA, Dawson J, Allison DB, Zhang Y, Becker KG, Bernier M, de Cabo R. The SIRT1 Activator SRT1720 Extends Lifespan and Improves Health of Mice Fed a Standard Diet. Cell Rep. 2014 Feb 25. pii: S2211-1247(14)00065-5. doi: 10.1016/j.celrep.2014.01.031. [Epub ahead of print] PubMed PMID: 24582957. 3: Nguyen GT, Schaefer S, Gertz M, Weyand M, Steegborn C. Structures of human sirtuin 3 complexes with ADP-ribose and with carba-NAD+ and SRT1720: binding details and inhibition mechanism. Acta Crystallogr D Biol Crystallogr. 2013 Aug;69(Pt 8):1423-32. doi: 10.1107/S0907444913015448. Epub 2013 Jul 17. PubMed PMID: 23897466. 4: Matsuya Y, Kobayashi Y, Uchida S, Itoh Y, Sawada H, Suzuki T, Miyata N, Sugimoto K, Toyooka N. Search for a novel SIRT1 activator: structural modification of SRT1720 and biological evaluation. Bioorg Med Chem Lett. 2013 Sep 1;23(17):4907-10. doi: 10.1016/j.bmcl.2013.06.070. Epub 2013 Jul 3. PubMed PMID: 23876989. 5: Ichikawa T, Hayashi R, Suzuki K, Imanishi S, Kambara K, Okazawa S, Inomata M, Yamada T, Yamazaki Y, Koshimizu Y, Miwa T, Matsui S, Usui I, Urakaze M, Matsuya Y, Sasahara M, Tobe K. Sirtuin 1 activator SRT1720 suppresses inflammation in an ovalbumin-induced mouse model of asthma. Respirology. 2013 Feb;18(2):332-9. doi: 10.1111/j.1440-1843.2012.02284.x. PubMed PMID: 23062010. 6: Suzuki K, Hayashi R, Ichikawa T, Imanishi S, Yamada T, Inomata M, Miwa T, Matsui S, Usui I, Urakaze M, Matsuya Y, Ogawa H, Sakurai H, Saiki I, Tobe K. SRT1720, a SIRT1 activator, promotes tumor cell migration, and lung metastasis of breast cancer in mice. Oncol Rep. 2012 Jun;27(6):1726-32. doi: 10.3892/or.2012.1750. Epub 2012 Mar 27. PubMed PMID: 22470132. 7: Minor RK, Baur JA, Gomes AP, Ward TM, Csiszar A, Mercken EM, Abdelmohsen K, Shin YK, Canto C, Scheibye-Knudsen M, Krawczyk M, Irusta PM, MartÃn-Montalvo A, Hubbard BP, Zhang Y, Lehrmann E, White AA, Price NL, Swindell WR, Pearson KJ, Becker KG, Bohr VA, Gorospe M, Egan JM, Talan MI, Auwerx J, Westphal CH, Ellis JL, Ungvari Z, Vlasuk GP, Elliott PJ, Sinclair DA, de Cabo R. SRT1720 improves survival and healthspan of obese mice. Sci Rep. 2011;1:70. doi: 10.1038/srep00070. Epub 2011 Aug 18. Erratum in: Sci Rep. 2013;3():1131. PubMed PMID: 22355589; PubMed Central PMCID: PMC3216557. 8: Chauhan D, Bandi M, Singh AV, Ray A, Raje N, Richardson P, Anderson KC. Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells. Br J Haematol. 2011 Dec;155(5):588-98. doi: 10.1111/j.1365-2141.2011.08888.x. Epub 2011 Sep 26. PubMed PMID: 21950728. 9: Huber JL, McBurney MW, Distefano PS, McDonagh T. SIRT1-independent mechanisms of the putative sirtuin enzyme activators SRT1720 and SRT2183. Future Med Chem. 2010 Dec;2(12):1751-9. doi: 10.4155/fmc.10.257. PubMed PMID: 21428798. 10: Zarse K, Schmeisser S, Birringer M, Falk E, Schmoll D, Ristow M. Differential effects of resveratrol and SRT1720 on lifespan of adult Caenorhabditis elegans. Horm Metab Res. 2010 Nov;42(12):837-9. doi: 10.1055/s-0030-1265225. Epub 2010 Oct 5. PubMed PMID: 20925017. 11: Funk JA, Odejinmi S, Schnellmann RG. SRT1720 induces mitochondrial biogenesis and rescues mitochondrial function after oxidant injury in renal proximal tubule cells. J Pharmacol Exp Ther. 2010 May;333(2):593-601. doi: 10.1124/jpet.109.161992. Epub 2010 Jan 26. PubMed PMID: 20103585; PubMed Central PMCID: PMC2872958. 12: Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, Griffith D, Griffor M, Loulakis P, Pabst B, Qiu X, Stockman B, Thanabal V, Varghese A, Ward J, Withka J, Ahn K. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem. 2010 Mar 12;285(11):8340-51. doi: 10.1074/jbc.M109.088682. Epub 2010 Jan 8. PubMed PMID: 20061378; PubMed Central PMCID: PMC2832984. 13: Yamazaki Y, Usui I, Kanatani Y, Matsuya Y, Tsuneyama K, Fujisaka S, Bukhari A, Suzuki H, Senda S, Imanishi S, Hirata K, Ishiki M, Hayashi R, Urakaze M, Nemoto H, Kobayashi M, Tobe K. Treatment with SRT1720, a SIRT1 activator, ameliorates fatty liver with reduced expression of lipogenic enzymes in MSG mice. Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E1179-86. doi: 10.1152/ajpendo.90997.2008. Epub 2009 Sep 1. PubMed PMID: 19724016.